Key facts
- It has raised $255.0M across 4 recorded rounds; the latest was PIPE ($200.0M) in Aug 2023.
- Inhibrx has filed 5 Form Ds with the SEC since 2018, most recently Aug 2023 ($200.0M sold to 5 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for Inhibrx
Create free account
No card required
Funding rounds
4 roundsAug 2023PIPE$200.0M▮
Apr 2020Later Stage VC$55.0M▮
About Inhibrx
- Industry
- Drug Discovery
PA Mark — not yet priced
Inhibrx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Inhibrx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Inhibrx in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.